RESUMEN
BACKGROUND: Specific bone-targeting drug delivery system is very important in the treatment of bone-related diseases. Development of nanotechnology provides a good platform and a new thought for preparation of specific bone-targeting nanoscale drug delivery system. OBJECTIVE: To review the current development and future prospects of specific bone-targeting drug delivery systems. METHODS: A computer-based online search of PubMed, Web of Science, and Medline databases was performed to retrieve studies regarding active targeting drug delivery system and nanoscale drug delivery system published between March 2014 and March 2019 with the search terms “Bone target therapy, Nanoparticles, Drug delivery system”. RESULTS AND CONCLUSION: The targeting group is an important component of the specific bone-targeting drug delivery system and it determines the targeting efficiency of the drug delivery system. Targeting bone tissue, osteoblasts, osteoblasts, and bone marrow mesenchymal stem cells have their own advantages and disadvantages. Specific bone-targeting nanoscale drug delivery systems have been widely used in various bone diseases, such as metastatic osteoporosis, osteomyelitis, multiple myeloma, osteosarcoma, and bone metastases. Specific bone-targeting drug delivery systems have advantages and challenges. Although many basic studies have shown good results of specific bone-targeting drug delivery systems in vivo, little is reported on successful clinical transformation of bone-targeting groups-modified nanoscale drug delivery systems.
RESUMEN
Antiangiogenic targeted therapy plays an important role in the treatment of malignant tumors,especially in the process of antitumor treatment including transformation stage,late stage,and maintenance stage.Apatinib(YN968D1)is a self-developed antian-giogenic targeted agent that was approved and launched for third-line and subsequent-line treatment for advanced gastric adenocarci-noma or gastro-esophageal junction adenocarcinoma.Moreover,the use of apatinib for other multiple solid tumors has been investi-gated.With an increase in the number of clinical studies on apatinib,concerns have been raised about its safety.Hence,we highlight the common adverse reactions of apatinib in clinical application and the incidences of various adverse events in different tumor treat-ments.We provide a comprehensive analysis of available clinical data and compare the advantages and disadvantages of apatinib with other common antiangiogenic drugs regarding their adverse reactions.Overall,these results will help to provide a better understand-ing of the safety of this medicine in the hope of helping physicians to provide patients with a safe and effective treatment.
RESUMEN
Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100%mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.